SGCD

sarcoglycan delta

Basic information

Region (hg38): 5:155870344-156767788

Links

ENSG00000170624NCBI:6444OMIM:601411HGNC:10807Uniprot:Q92629AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autosomal recessive limb-girdle muscular dystrophy type 2F (Definitive), mode of inheritance: AR
  • autosomal recessive limb-girdle muscular dystrophy type 2F (Moderate), mode of inheritance: AR
  • familial isolated dilated cardiomyopathy (Supportive), mode of inheritance: AD
  • autosomal recessive limb-girdle muscular dystrophy type 2F (Supportive), mode of inheritance: AR
  • autosomal recessive limb-girdle muscular dystrophy type 2F (Strong), mode of inheritance: AR
  • dilated cardiomyopathy 1L (Disputed Evidence), mode of inheritance: AD
  • autosomal recessive limb-girdle muscular dystrophy (Definitive), mode of inheritance: AR
  • dilated cardiomyopathy (Limited), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Cardiomyopathy, dilated, 1LARCardiovascularThe condition can include severe cardiac manifestations, and knowledge may allow surveillance (eg, with EKG, echocardiogram, and Holter monitoring) and early medical management, which may ameliorate morbidity and mortality; Heart transplantation may be indicated in individuals with severe dilated cardiomyopathyCardiovascular; Musculoskeletal8841194; 8776597; 10735275; 9832045; 10069710; 10974018,; 18285821; 19259135
Digenic inheritance (with SGCB) has been suggested, but the evidence is unclear

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SGCD gene.

  • Autosomal recessive limb-girdle muscular dystrophy type 2F (16 variants)
  • Dilated cardiomyopathy 1L (4 variants)
  • not provided (4 variants)
  • Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F (2 variants)
  • Abnormality of the musculature (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SGCD gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
91
clinvar
1
clinvar
94
missense
1
clinvar
150
clinvar
2
clinvar
2
clinvar
155
nonsense
8
clinvar
2
clinvar
3
clinvar
13
start loss
1
clinvar
1
frameshift
10
clinvar
9
clinvar
19
inframe indel
4
clinvar
4
splice donor/acceptor (+/-2bp)
9
clinvar
8
clinvar
1
clinvar
18
splice region
10
17
27
non coding
140
clinvar
160
clinvar
50
clinvar
350
Total 18 21 308 254 53

Highest pathogenic variant AF is 0.0000131

Variants in SGCD

This is a list of pathogenic ClinVar variants found in the SGCD region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-156050855-TTGTGCCTCCATTTTACAAGAACCCTTTGATTACATTGGGCCAACATGGATAATCCAGGCTAATCTTCCCACCTCAGGATCCTTAATGTTATCACATTGCTAAGTCTCTTTTGACATAAAAGGTAACTTATTCCCTTGTCCCAGGGATTGGCACATGAGCATTCTTGGAGAACCATTACTCAGCCTTTCACATATACCTTTACTAGAAACTAATATTATAGCTGAAATAAACACTAAGCATTTCATTTTAAAAAAGGTTTGTTTGCCTTCTTAAAATACATTATGAAATTTGATAAATGAGTATTATGGATTGTTATTAAAAACAGAGAGAAACCAAGGAAGAGAGGGAGGAAAGAAAGGGGGAAAATATTTTCCCAGAGAAGTTTGAATTTGAGTTTATCACTCTAGAAAATTTCACTTTCCTCTCAAATTTAGCTTACTAAATTTCCAAAGTGACACTGCATTTCTCTTCTTCCATGAATTACTTAAGATTCATAAGTACCCTGGTTAATAGTCCAGTGACTGGGTTGAGACTTGAAAATAAATATGCAAATTTATATTTGACCACATGGAGAGAGATGGGAGCTGTCTGCTTTTTGGCAAACTGAATAACTATATATAATATACCCAGTGTTCCAACTTTGAATGCTTCCAAATCTTTATGCAAGATAGTACAACAAATACTATAATATATTTATTCATTTAACAATTAATTGTTGAGCTCCATGCAGGAGGTACTAAGGTGAGAACCCAATATAGGTTGATTAAGAAAACAGACATGCTTGTGTGTGTGAAACATATAAACTAGAGGGGAAGGCAGACAGAAAAAGTAAAAAACTAAACAAACAAATATATAAATGAGCACTCGTGGTAGGAAGGAACAAGCATAGTGCAATAGGAAGGCTTAGGAAGGAGATTGAAGAGTTTTCTCTGTGGATAAACCTGAAGTTTGGGAAGGAGCCAACCCTGTCTGTATGTTTTAGTGCATGTAGTGTGTGCTGGGGGAAAGAGGTGGGGAAGGGTTGTTGTTCTGAGCAGAGGGAATGGGATGTGAAATGCTGGTGGAGGTGGAAGGCGTTATGATGTTGTGTCAGGCCTTTTCCTTAGTTCAGCTAAAGACAGGGTTCTTGTCCATCCCATGGCCACAAAAATTTATGCTCACAGACAGTTTAAAGGGTAAGTAAAGCAGGATTTTATTGGGTGAAAAAGGGAAAAAAGGGGAAACAGGGATCCTCCATAAGTCCAGAGTTCCTGCTAGAGCACTTCCGCCCACAGCTTGAATCCCAAGTTCCACCCAAGAAGAGGAGGGGCCAGGCTGCCCTCTGCTGCAAATGTCGTGAACTTCCTGAGGCTCCACCTCAGTAGACAGGCTGGTTGGAGTTTCTCCAGGGATCCCCTCCCACCTGGCTGTCTCAGTGTCGGGGGTAAGGGGTGAAGAGTTTGGTGTGTTCAAGTGGTAGGACAGAAGCCATTGTGGCTGGAATATTACAGATGAAAGGGGAGAGGCTGGCAGGGTTTGGTTCACACAAGGCTTTGTAGGTCATGAGAAGGCCTTTGAACTTCATGCTAAGTGTGATGAAAGGAAGCCTAGGGGCTTGGAGGACTAAGTTTATAAAAGATTACTCTGGGTATTGTGAGCAGAATAAACTGTTGGGCCAGGGCTAGTTGGAAGGTTAGAGAAGCAGGGTGGTGAGATATATAGAAATGAAGACATGTGAACATGGAATATATTTTAGTGGTAGAAACAATAGAGTTTGCAGATAGAAAATATATGTCGTATAAATGAGGACTCCTAGCAGGGCTGGCTGCATACTTTGTGAAACACAGTGCAAAATGCAGGGTTCCTTGTTAAAGGAGTAAAAAAAAAAGTGCCATTAAAGGTACTAAAGTGTAAAACTGTTTGCTTTCTTCCATGTCTCTCTTGCCATCTGTCATGATGGTGTTTTATTTGCTGCTTAATGTCACATTAACTTGGGCACAGGGATATTTGCCAGACAAAGTCCAGACCCTTGCAGGCTCCCTGGGGTTTTGCCCAGAGACTCAATTGGGGCAGAGTTAATCACTGCTGGGTTTCCTCTTATGCAAGCTCTAGGACCAATGTGTTGTGCCCCCCTGGGGACAGGAAAGTCAATCTTCCCTTCCCACAGGTCCACTGCCTCGTCCACAGCAAACAGGCAACCCCCAAGGTTATTGGAGCCCCTGATCCAGGACACACTTGATACTTGAATTAGGGTGGGCAAAAGGCTTGTCCCTACCTAGTAGCTAGCTGAACATACATATGGCACTGCCAGTTGGGGCATTTACAACCACTACCATGCCCTACTTGAGACACCACAGGGTGATTGGTGTGTGTGCTCATCCTCAACCCTCCCCTTGCCCAGGCTGCTGCTGAAGGTTAAGGGCTATAGCAGAATGCAGCACCACTCCCCAGTCCCCGGCCATGTAACATGGTCACCATCCTGGACAGAGGGCAGCAGCTGTCACTGCTCAGTGACAGGGAAGCCGAAGGTGAAAAAGGCCCAGGATGAACAGGAGACAGGGGGCTGAGAATCCATCTAAAAGGTAGTGAGGGGGTGAGAGGCAGGACTACATGTGAGCCAAACTCCAAGCACTCAGTATGCTCCTTTGTCCCATTGAACTTCACTTATAAAATGCAAATTAGAAGATAAAATTAAGAATGTAAAGACTGCAACCACAGAACATTAAACTCCAAGTGCAGGACCCTCTGAGCTTGGAGCTCTTGTGTGATTCCCCTGGCCATGTGCCTATGAAGCCAGCCTTAACTTTTGGGGTTTTGACTTAAGCACCTTGGCAAATGTTGGTACCACATAATGAAATAGAGAAGATGGAAACAATCCAGTTTGCAAGATACCTTAGTGCATTCAGGCTGCTATAACAAAATACTTTAAGCTGGGTAGTTATAAACAACAGAAATTTATTGCTCACAGTTATGGGGCCTGCAAAGTTCAAAATCAAGATGCTGGCAGATTCAATATCTGGTGAGTGCCATTCCTCACGGATGACATCTAGCTTTGTCCCCACATGGTGGAAGGGGCAAGGGAGCTCATCTGAGCTGCTTCTGTAGGGGCACTGATTCCATTGACGAGGGTAGAGTTCTCATAACTTAATGACTTCCCAAAGGCCCTACCGCTTAATACTATCATAGTGTGAACCAGGTTCCGATATATGAAATGAGAGGGACACCAACATTCAGACCACAGCACAAAGGCAAATCATATATATTTGGGTGGAGATGTCAAGTAAGAAATTGGGAATATAAGTCTAGAGCTTATTTAGTTCCGGAGGTTTTGAAATATTCAGGGCCGTAGTCTGATATTCCCATTACCACTTTCTTGCAAAGCTAAAGTGCAACACCAAACATCTGGATGTTTGGATTCCAGTTAAACCAATTAAACATGAACTTTCCTTCTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTCGCTCTGTGGCCCAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACGGCAAGCTCCGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCAACTACCTGGGACTACAGGCACCCGCCACCACGCCTGGCTAATTTTTTGTATTTTTAGTAGAGACGGCGTTTCACCGTGTTAGCCAGGATGGTCTCAATCTCCTGACCTCGTGATCCACCCGCCTCAGCCTCCCAAAGTGATGGGATTACAGGCGTGAGCCACCGCGCCCGGCCCCTAAACATGAACTTTCTATATTTAAATATCTCAAAACATTTTTGCAAAAGGCCAGATAATGTTTATTTGACTGCAATATTAATGTATTTTCAGAAGCCTTTCTTTATCATATACATGTGTATATTCATTATCCCATTTCTTTTCTCTTTCCTAAACTTGAAGTAGCATTTTTGTTTGTCAGGCTAATATTAACTCTTGAATTATTCTGATTTATTGAGTACATAATTCTATATTAAGTTATAAATACACAAACAGGGTTACTGGACTTTACATTATTCTTAAACTCAAAATGGAGAGCTGGGCTTGATTCTTTCACCTCAAATATAGTTGAAACCAGAAAACCTGGACAGTGTGCCAGTCATTCTATTTTTTCACTCATTCAGTTTATAGGTGTGGTCCAAAAGGAAGCTGTTTTAAGCCCACCCTGTCCCTGTTGTGTGTGACAGGGAGCCAAAAATATGTCTGTGCTCAGAGGAGTTAGGAGATGTTTGCCTTCAGGTAGTATGTGAGAGAAAACTTTCTCCAATTCTTTGCCTATAGCAGTGCCAGCTTCCAGTTTTCTATTTTTTTTTTTCCCCATAGAAGAATTCAGCCCTGAGGCTACTCCTTTTTTTTCTTTCTTTCTTTCTTTTCTTTTTTTTCTTAAAAGACAAAATAAAGTAGCCTCTGATAGACTATGAGAAGAAAAGTAGTAAAGGTGGCTGTTGATTAAGCTGTGACTTATGTCTTTGACATCTATGCGGGTCACTTCTAAATTGGGTCTCTTCCAAAGAACATCAGAGAAAACTAGAAACATGTTTATTAAAGTCCCCAGATGATTATTCTGTATCCTCTTCCAGTTAATGCTCCAGACACCCCACTGAAAGCAGGGACATATCTAGAAATTATGTTAAAGGTAAATCTCTCTTGTAGATGAATATGGATTTGAAGATTGTTACTTGGTGTTCACCCAGTCACAGTGACCTAGTTTTAAGGAAGTACGTCTCACATATACCTCTACTATCATTAGGTGGCAAAGAAAGGAGATTTCAAGGGACAGTGTTTAGACTATATATTTTAAAGGAAATGTACTCTTTAACAAACCTAATTTATCTGAAAATTAGATTTAAACTAGCTGGATGCCTGGTAAATAAGAGGCAGTCAGTAAATATTTGTAGGACTTAAATTAGGCATGCATCTCTTCTAGCCTCAGAGCCATATACTCTAGTTCAGCAGCCAGAAAGGAGTCTAAAAAGTTAATTCATCATGCAGGTAATAAAGCTTGCCACAATGAAAGCATGGTATTACATGCTTAGTGGAATAAAAAACAGAATGGATAGGTAGAGTAACAGCCCTGACTTCTAACGACTTAGAGGACACTAAAACTTACAAAATGTGTTAGAATTATATATATATTTAAAGCTAAAGGAAAATTTTAAAAAGTCACCTAGTCTAACCAGTGTGGACTAGACTTATCAGTCAGAAATAGTGACAAAGTTGAAGTCAGATGCTGCTCTTAGTCCAGTATTCATTCCAACTGATGTCACTCTTGCAAAAATTGTGACAGTAAGAAAATTATAACAATGACAGAGATCTGACCTAACTGACTCCATCTTACTTCTAACCTCCAAGCTACCCTTATTTATTCCTGAGTGTAGGCTGAACTAACTTTGGGAGGAACTTAGTTTATAGTTTAACTCTGAAACAAAGATGATAACAGCCCTTTACTGAAACAAATCCCTTTCTTGCCTGGGGACCAGACTGCCTTTGTAGGACTAACAAATTATGGTTTAGGAGTCATGCAGCCAGGGGCCACAAGATTCCAAACTTCTCCAGTTGTTCCTATGAATAACATCAATATTGTAGGACCTAATATCAGTGCTCAAGATATTTTTCAGACCCCGAATTCTGATGCACCAGCTGATGCTACCCCAGACCAGTAATCTGGCTCAGCTAGTTCTGCCATCTCACCCAGGAACAGAAGACAGCAAGAAGAACACACTTTGATCTATGATTTCATCTCCTACCCCAACCAATCAACTCTTCTCATTCTCTGGTCCCCTACCTGCCAAATTATCCTTAAAAAAAAAAAAAAAAAAAACAGTCTCCAAATTTTCAGAGAGGCTGATTTAAGTAATAAAACTCCAGTTTCCCATTTAGCCAGCTGAGCGTGAATTAAACGTTTTCTCTATTGCAATTCTCCTGTCTTGATAAATCAGTGCTATCTGGGCAGTAGGCAAGGAGAATCTGTCGGGTGGTTACACAACTATAACCACTGGGCATTTTTTGAAAGTACTTTATGAATCCTCTTGTTGCCTTATCTGTGGCAAGCGATGACTGATACCTACTTAGTGTAATAGGTTGTTCAAAGCAGTTTTATCAAGACAGGGTGGAAACTAGCGCATCCCTAAGTACGTTTGAAATACTCCATGCAAGTGGTTTATCTATACAGATAGTCATTAATGCATTTAAAATTGTGATCCATAGAAAACAGCTTGGATGTTCAGTAATAAAGAATAAATAGACTATCTCTTAGCTGTCAAAAATGAAACTGTAGAAGAGTAGTTAATGACATAGGAAAATATTCACTATGTAAAATTATGTAGAAATATATCTTGCATTATAGTATTATCCCATTAATATATGCATTGCCTATCATTTCA-T Small for gestational age • Large for gestational age not provided (-)156996
5-156117876-A-G Benign (May 01, 2022)1695144
5-156326646-CTGTAATAAGCT-C Autosomal recessive limb-girdle muscular dystrophy type 2F;Dilated cardiomyopathy 1L • Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L Benign/Likely benign (Feb 08, 2023)556599
5-156326739-C-A Benign (Mar 03, 2015)1183373
5-156326864-A-T not specified • Qualitative or quantitative defects of delta-sarcoglycan Conflicting classifications of pathogenicity (Jan 12, 2018)48113
5-156326872-G-A not specified • Qualitative or quantitative defects of delta-sarcoglycan • Limb-girdle muscular dystrophy, recessive • Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L • Autosomal recessive limb-girdle muscular dystrophy type 2F Likely benign (Feb 08, 2023)165220
5-156326898-G-T not specified • Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F Uncertain significance (Dec 27, 2016)178658
5-156326901-A-G Benign (Mar 03, 2015)1247592
5-156326904-C-G not specified • Qualitative or quantitative defects of delta-sarcoglycan Conflicting classifications of pathogenicity (Jan 13, 2018)48112
5-156326924-T-C not specified • Qualitative or quantitative defects of delta-sarcoglycan • Limb-girdle muscular dystrophy, recessive Conflicting classifications of pathogenicity (Jan 12, 2018)165222
5-156326941-T-G Qualitative or quantitative defects of delta-sarcoglycan Uncertain significance (Jan 13, 2018)905224
5-156326973-A-T not specified • Limb-girdle muscular dystrophy, recessive • Qualitative or quantitative defects of delta-sarcoglycan • Dilated cardiomyopathy 1L • Autosomal recessive limb-girdle muscular dystrophy type 2F Benign/Likely benign (Feb 08, 2023)48111
5-156327060-C-G Benign (Mar 03, 2015)1294203
5-156327097-A-G not specified • Limb-girdle muscular dystrophy, recessive • Qualitative or quantitative defects of delta-sarcoglycan • Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L Benign/Likely benign (Feb 08, 2023)48110
5-156327123-GGGCCTGCACACACTCAGCGGGCCGAGT-G not specified not provided (Apr 10, 2014)178835
5-156327136-C-CT Autosomal recessive limb-girdle muscular dystrophy type 2F;Dilated cardiomyopathy 1L Uncertain significance (Apr 24, 2018)558030
5-156327141-C-T Limb-girdle muscular dystrophy, recessive • Qualitative or quantitative defects of delta-sarcoglycan • Autosomal recessive limb-girdle muscular dystrophy type 2F;Dilated cardiomyopathy 1L • Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L Conflicting classifications of pathogenicity (Feb 08, 2023)352330
5-156327182-C-G not specified • Qualitative or quantitative defects of delta-sarcoglycan • Limb-girdle muscular dystrophy, recessive • Dilated cardiomyopathy 1L • Autosomal recessive limb-girdle muscular dystrophy type 2F Benign (Feb 08, 2023)48114
5-156327196-G-T not specified Likely benign (Jun 22, 2016)387039
5-156327217-G-A not specified • Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F • Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L Conflicting classifications of pathogenicity (Feb 08, 2023)177991
5-156327232-G-T not specified • Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F Uncertain significance (Feb 16, 2017)165225
5-156327233-G-A Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F Uncertain significance (Jun 28, 2017)552679
5-156327233-G-C Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F Uncertain significance (Mar 16, 2018)557336
5-156327232-G-GGT Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F • Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L Uncertain significance (Feb 08, 2023)555052
5-156327234-T-A Dilated cardiomyopathy 1L;Autosomal recessive limb-girdle muscular dystrophy type 2F • Autosomal recessive limb-girdle muscular dystrophy type 2F • Dilated cardiomyopathy 1L Uncertain significance (Feb 08, 2023)554848

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SGCDprotein_codingprotein_codingENST00000337851 8897446
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.002070.9801246250121246370.0000481
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.1951441510.9550.000007751842
Missense in Polyphen4450.6920.86799641
Synonymous-0.1816159.21.030.00000318580
Loss of Function2.08715.90.4399.44e-7187

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001940.000194
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.00004670.0000464
European (Non-Finnish)0.00006280.0000619
Middle Eastern0.000.00
South Asian0.00003530.0000327
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.;
Disease
DISEASE: Limb-girdle muscular dystrophy 2F (LGMD2F) [MIM:601287]: An autosomal recessive degenerative myopathy initially affecting the proximal limb girdle musculature. Muscle from patients shows a complete loss of delta-sarcoglycan as well as of the others components of the sarcoglycan complex. {ECO:0000269|PubMed:9832045}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1L (CMD1L) [MIM:606685]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:10974018}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Dilated cardiomyopathy (DCM) - Homo sapiens (human);Viral myocarditis - Homo sapiens (human);Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human);Hypertrophic cardiomyopathy (HCM) - Homo sapiens (human);Arrhythmogenic Right Ventricular Cardiomyopathy (Consensus)

Recessive Scores

pRec
0.368

Intolerance Scores

loftool
0.276
rvis_EVS
-0.27
rvis_percentile_EVS
34.32

Haploinsufficiency Scores

pHI
0.150
hipred
Y
hipred_score
0.668
ghis
0.547

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.789

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Sgcd
Phenotype
behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); muscle phenotype; homeostasis/metabolism phenotype;

Zebrafish Information Network

Gene name
sgcd
Affected structure
ventricular myocardium
Phenotype tag
abnormal
Phenotype quality
decreased contractility

Gene ontology

Biological process
muscle organ development;cell death;calcium-mediated signaling;cellular protein-containing complex localization;cardiac muscle tissue development;cardiac muscle fiber development;calcium ion homeostasis;heart contraction;coronary vasculature morphogenesis;cardiac muscle cell contraction
Cellular component
cytoskeleton;plasma membrane;dystrophin-associated glycoprotein complex;sarcoglycan complex;integral component of membrane;sarcoplasmic reticulum;sarcolemma
Molecular function